M Drummond

462 total citations
23 papers, 320 citations indexed

About

M Drummond is a scholar working on Economics and Econometrics, General Health Professions and Pharmacology. According to data from OpenAlex, M Drummond has authored 23 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 3 papers in General Health Professions and 3 papers in Pharmacology. Recurrent topics in M Drummond's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (6 papers) and Pharmaceutical industry and healthcare (3 papers). M Drummond is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (6 papers) and Pharmaceutical industry and healthcare (3 papers). M Drummond collaborates with scholars based in United Kingdom, United States and Australia. M Drummond's co-authors include R. Taylor, Sean D. Sullivan, Glenn Salkeld, Linda Davies, M Aristides, C.D. Forbes, James Mason, Peter Tugwell, S. E. Gabriel and Roger Hawkes and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and British journal of surgery.

In The Last Decade

M Drummond

20 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M Drummond United Kingdom 9 196 91 55 52 26 23 320
Julie Sakowski United States 13 142 0.7× 83 0.9× 51 0.9× 18 0.3× 48 1.8× 18 446
Vida Hamidi Norway 7 142 0.7× 65 0.7× 24 0.4× 8 0.2× 54 2.1× 17 299
Karen Worley United States 11 83 0.4× 67 0.7× 17 0.3× 15 0.3× 15 0.6× 21 351
Tomáš Tesař Slovakia 14 249 1.3× 54 0.6× 62 1.1× 5 0.1× 23 0.9× 49 440
Kirsten Axelsen United States 9 229 1.2× 37 0.4× 28 0.5× 4 0.1× 23 0.9× 14 343
Aisha Vadhariya United States 8 69 0.4× 37 0.4× 27 0.5× 5 0.1× 23 0.9× 32 279
L. M. Schwartz United States 4 40 0.2× 41 0.5× 37 0.7× 111 2.1× 22 0.8× 4 322
Dimitra Lambrelli United Kingdom 10 43 0.2× 41 0.5× 17 0.3× 8 0.2× 39 1.5× 37 315
Kun Zhao China 9 170 0.9× 106 1.2× 21 0.4× 5 0.1× 37 1.4× 44 364
Suhui Li United States 11 112 0.6× 129 1.4× 28 0.5× 4 0.1× 27 1.0× 23 338

Countries citing papers authored by M Drummond

Since Specialization
Citations

This map shows the geographic impact of M Drummond's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Drummond with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Drummond more than expected).

Fields of papers citing papers by M Drummond

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M Drummond. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Drummond. The network helps show where M Drummond may publish in the future.

Co-authorship network of co-authors of M Drummond

This figure shows the co-authorship network connecting the top 25 collaborators of M Drummond. A scholar is included among the top collaborators of M Drummond based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M Drummond. M Drummond is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Drummond, M, et al.. (2022). P48 Are Health Technology Assessment (HTA) Bodies Responding to the Assessment Challenges Posed By Cell and Gene Therapies?. Value in Health. 25(7). S297–S297. 1 indexed citations
2.
Corbacho, Belén, et al.. (2015). Regional Versus Centralized Hta: Implications for the Assessment of Cancer Drugs. Value in Health. 18(7). A342–A342. 1 indexed citations
3.
Taylor, R., M Drummond, Glenn Salkeld, & Sean D. Sullivan. (2004). Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 329(7472). 972–975. 133 indexed citations
4.
Drummond, M. (2003). Will there ever be a European drug pricing and reimbursement agency?. The European Journal of Health Economics. 4(2). 67–69. 16 indexed citations
5.
6.
Gabriel, S. E., Peter Tugwell, & M Drummond. (2002). Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology. Annals of the Rheumatic Diseases. 61(4). 370–373. 14 indexed citations
7.
Milne, Robert, et al.. (2002). Predicting faults with real-time diagnosis. 2. 2598–2603.
8.
Mason, James, Nick Freemantle, Irwin Nazareth, et al.. (2001). When is it cost-effective to change the behaviour of health professionals ?. Durham Research Online (Durham University). 14 indexed citations
9.
Lynch, Vincent J., et al.. (2001). The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia. European Psychiatry. 16(5). 307–312. 10 indexed citations
10.
Drummond, M, et al.. (2001). PCN11: ECONOMIC EVALUATION OF LIPOSOMAL DOXORUBICIN VS TOPOTECAN FOR RECURRENT OVARIAN CANCER IN THE UK. Value in Health. 4(2). 88–88. 1 indexed citations
11.
Drummond, M. (2000). Health economic models. Lara D. Veeken. 39(suppl_2). 29–32. 6 indexed citations
12.
Sangha, O. & M Drummond. (2000). Introduction. Lara D. Veeken. 39(suppl_2). 1–2. 1 indexed citations
13.
Drummond, M, et al.. (1999). Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer. Journal of Medical Economics. 2(1-4). 33–43. 10 indexed citations
14.
Milne, Robert, et al.. (1998). PREDICTING MAKING DEFECTS ONLINE USING DATA MINING. 11. 33–38. 1 indexed citations
15.
16.
Drummond, M, et al.. (1996). Methodological issues in the outcomes assessment of a new, atypical antipsychotic. European Neuropsychopharmacology. 6. S4–126. 2 indexed citations
17.
Mason, James & M Drummond. (1995). The DH register of cost-effectiveness studies: content and quality.. PubMed. 27(2). 50–6. 11 indexed citations
18.
Drummond, M, M Aristides, Linda Davies, & C.D. Forbes. (1994). Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. British journal of surgery. 81(12). 1742–1746. 57 indexed citations
19.
Drummond, M, et al.. (1992). Funding research and development in the NHS. The Lancet. 339(8787). 230–231. 7 indexed citations
20.
Drummond, M, et al.. (1991). Fundholding in general practice and financial risk.. BMJ. 302(6792). 1582–1584. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Julie Sakowski Breakdown of academic impact, for papers by Vida Hamidi Breakdown of academic impact, for papers by Karen Worley Breakdown of academic impact, for papers by Tomáš Tesař Breakdown of academic impact, for papers by Kirsten Axelsen Breakdown of academic impact, for papers by Aisha Vadhariya Breakdown of academic impact, for papers by L. M. Schwartz Breakdown of academic impact, for papers by Dimitra Lambrelli Breakdown of academic impact, for papers by Kun Zhao Breakdown of academic impact, for papers by Suhui Li
Rankless by CCL
2026